Hyperosmotic dehydration can reduce brain water content and intracranial pressure. It enters the cerebrospinal fluid and brain tissue more slowly and is cleared more slowly. Most of it is metabolized into CO2 and water and excreted.

Hyperosmotic dehydration can reduce brain water content and intracranial pressure. It enters the cerebrospinal fluid and brain tissue more slowly and is cleared more slowly. Most of it is metabolized into CO2 and water and excreted.

[Pharmacology and Toxicology] Glycerol fructose injection is a hypertonic preparation. Through high osmotic dehydration, it can reduce the water content of the brain and reduce intracranial pressure. This product has a slow onset of action in reducing intracranial pressure and lasts for a long time. [Pharmacokinetics] This product enters the body tissues through the blood, and its distribution reaches equilibrium in about 2 to 3 hours. It enters the cerebrospinal fluid and brain tissue slowly and is cleared slowly. Most of this product is metabolized to CO2 and water for excretion.

[Pharmacology and Toxicology] Glycerol fructose injection is a hypertonic preparation. Through high osmotic dehydration, it can reduce the water content of the brain and reduce intracranial pressure. This product has a slow onset of action in reducing intracranial pressure and lasts for a long time. [Pharmacokinetics] This product enters the body tissues through the blood, and its distribution reaches equilibrium in about 2 to 3 hours. It enters the cerebrospinal fluid and brain tissue slowly and is cleared slowly. Most of this product is metabolized to CO2 and water for excretion.

This product is a cerebral vasodilator that can inhibit phosphodiesterase activity, increase the effect of vascular smooth muscle relaxation messenger C-GMP, selectively increase cerebral blood flow, and also inhibit platelet aggregation, reduce human blood viscosity, enhance red blood cell deformability, improve blood fluidity and microcirculation, promote brain tissue to absorb glucose, increase brain oxygen consumption, and improve brain metabolism.

Quinolone is a broad-spectrum antibiotic that has bactericidal effects on Gram-negative bacteria, Gram-positive bacteria and some anaerobic bacteria. It has good antibacterial effects on methicillin-resistant Staphylococcus aureus, ampicillin-resistant influenza bacilli, pipemidic acid-resistant Escherichia coli and bacteria resistant to other drugs. Its antibacterial mechanism is to inhibit the activity of bacterial DNA helicase, thereby inhibiting bacterial DNA transcription and replication, and has bactericidal effects on a variety of Gram-positive and Gram-negative bacteria.

This product is a highly selective 5HT3 receptor antagonist, which has a good preventive and therapeutic effect on nausea and vomiting caused by radiotherapy, chemotherapy and surgery. It inhibits the occurrence of nausea and vomiting by antagonizing the 5HT3 receptors in the central chemoreceptor area and peripheral vagus nerve endings. This product has high selectivity and no side effects such as extrapyramidal reactions and excessive sedation.

This product belongs to the quinolone antibacterial drug, which is the levorotatory form of ofloxacin. Its antibacterial activity is about twice that of ofloxacin. The main mechanism of action is to inhibit the activity of bacterial DNA gyrase and the replication of bacterial DNA. It has the characteristics of broad antibacterial spectrum and strong antibacterial effect, and has good antibacterial effect on most Enterobacteriaceae, some Staphylococci, Streptococcus pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Chlamydia, etc.